News
Media Coverage

Thursday, November 20, 2014

Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s

https://phcoct.org/liquid-viagra-rui/ get link professional dissertation writing services go site https://yeproc.com/pay-someone-to-do-your-research-paper-5127/ source site xnxx india how do i outline a research paper viagra professional canada do write my paper click cialis only works sometimes https://skincitybodypainting.com/2696-buy-completed-coursework/ writing dates in spanish research reporting guidelines follow site levitra generic vardenafil descartes essays sildenafil bei diabetes https://sun-world.com/blog/creative-writing-courses-leeds/15/ how to write a movie essay how to change my icloud email address on my iphone nolvadex bodybuilding side effects buy herbal viagra nz https://www.iama.edu/clinics/generique-viagra.html viagra before stress test marketing plan example enter https://www.flseagrant.org/news/online-homework-help-statistics/29/ https://yeproc.com/college-essays-for-sale-forest-primeval-547/ source buy viagra online uk AlzforumStem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimer’s disease. That is about to change, according to scientists who spoke at “Accelerating the Cure for Alzheimer’s Disease through Regenerative Medicine.” READ MORE HERE

Wednesday, August 20, 2014

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Alzheimer's News TodayAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies developing stem cell therapies for Alzheimer’s disease and dementia. READ MORE HERE

Stemedica Posts Alzheimer’s Stem Cell Data

BioPortfolio LogoStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE

Stemedica International Posts Alzheimer’s Stem Cell Data

DD&D MagStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE